BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...was VP, global regulatory strategy head, oncology I at Bayer AG (Xetra:BAYN). Rare disease company SymBio Pharmaceuticals Ltd....
...Therapeutics Inc. Flatiron Health Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision BioSciences Inc. Quell Therapeutics Ltd. Roche SymBio Pharmaceuticals Ltd. Unum...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NASDAQ:OCUL) Sustained-release travoprost insert Glaucoma Phase III data 1H19 Onconova Therapeutics Inc. (NASDAQ:ONTX) / SymBio Pharmaceuticals Ltd....
BioCentury | Jan 19, 2018
Clinical News

Onconova expands enrollment in Phase III INSPIRE trial of rigosertib in MDS

...Rigosertib is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1; STPK13). SymBio Pharmaceuticals Ltd....
...a 2011 deal (see BioCentury, July 11, 2011 ). Onconova Therapeutics Inc. (NASDAQ:ONTX), Newtown, Pa. SymBio Pharmaceuticals Ltd....
...hematologic improvement rate Status: Phase III amended Milestone: NA Jaime De Leon IV rigosertib ON 01910.Na SyB L-1101 Onconova Therapeutics Inc. SymBio Pharmaceuticals Ltd. Phosphoinositide...
BioCentury | May 26, 2017
Clinical News

SymBio suspends enrollment in Phase III of Ionsys

...the product from Johnson & Johnson (NYSE:JNJ). In a 2015 deal, The Medicines Co. granted SymBio...
...BioCentury, Dec. 17, 2012 & Oct. 26, 2015 ). The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. SymBio Pharmaceuticals Ltd....
...system application Status: Phase III suspended enrollment Milestone: NA Alicia Parker fentanyl iontophoretic transdermal system Ionsys SyB P-1501 Johnson & Johnson SymBio Pharmaceuticals Ltd. The...
BioCentury | Sep 5, 2016
Clinical News

Treakisym bendamustine regulatory update

...or refractory low-grade B cell non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). Last December, SymBio...
...Singapore. SymBio granted Eisai exclusive rights to the product in Japan, South Korea and Singapore. SymBio Pharmaceuticals Ltd....
BioCentury | Jul 11, 2016
Clinical News

Fentanyl iontophoretic transdermal system: Phase III started

...which had licensed the product from Johnson & Johnson. Last October, The Medicines Co. granted SymBio...
...and commercialize SyB P-1501 in Japan (see BioCentury, Dec. 17, 2012 & Oct. 26, 2015). SymBio Pharmaceuticals Ltd....
BioCentury | Dec 21, 2015
Clinical News

Oral rigosertib: Additional Phase I/II data

...reported data from the Phase I portion of the trial (see BioCentury, Nov. 17, 2014). SymBio...
...under a 2011 deal (see BioCentury, July 11, 2011). Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. SymBio Pharmaceuticals Ltd....
BioCentury | Oct 26, 2015
Company News

Medicines Co., SymBio deal

...The Medicines Co. granted SymBio an exclusive license to develop and commercialize Ionsys fentanyl iontophoretic transdermal...
...Ionsys from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. SymBio Pharmaceuticals Ltd....
BioCentury | Jul 13, 2015
Clinical News

IV rigosertib: Additional Phase III data

...Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan Product: IV rigosertib ( Estybon...
...company plans to start a Phase III trial of rigosertib in patients with higher-risk MDS. SymBio...
BioCentury | Jan 19, 2015
Financial News

SymBio financial update

...SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan Business: Cancer, Hematology, Autoimmune Date announced: 2015-01-13 Note: SymBio is...
...level I ADR program on the OTC market. Each ADR will represent one common share. SymBio...
Items per page:
1 - 10 of 133
BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...was VP, global regulatory strategy head, oncology I at Bayer AG (Xetra:BAYN). Rare disease company SymBio Pharmaceuticals Ltd....
...Therapeutics Inc. Flatiron Health Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision BioSciences Inc. Quell Therapeutics Ltd. Roche SymBio Pharmaceuticals Ltd. Unum...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NASDAQ:OCUL) Sustained-release travoprost insert Glaucoma Phase III data 1H19 Onconova Therapeutics Inc. (NASDAQ:ONTX) / SymBio Pharmaceuticals Ltd....
BioCentury | Jan 19, 2018
Clinical News

Onconova expands enrollment in Phase III INSPIRE trial of rigosertib in MDS

...Rigosertib is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1; STPK13). SymBio Pharmaceuticals Ltd....
...a 2011 deal (see BioCentury, July 11, 2011 ). Onconova Therapeutics Inc. (NASDAQ:ONTX), Newtown, Pa. SymBio Pharmaceuticals Ltd....
...hematologic improvement rate Status: Phase III amended Milestone: NA Jaime De Leon IV rigosertib ON 01910.Na SyB L-1101 Onconova Therapeutics Inc. SymBio Pharmaceuticals Ltd. Phosphoinositide...
BioCentury | May 26, 2017
Clinical News

SymBio suspends enrollment in Phase III of Ionsys

...the product from Johnson & Johnson (NYSE:JNJ). In a 2015 deal, The Medicines Co. granted SymBio...
...BioCentury, Dec. 17, 2012 & Oct. 26, 2015 ). The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. SymBio Pharmaceuticals Ltd....
...system application Status: Phase III suspended enrollment Milestone: NA Alicia Parker fentanyl iontophoretic transdermal system Ionsys SyB P-1501 Johnson & Johnson SymBio Pharmaceuticals Ltd. The...
BioCentury | Sep 5, 2016
Clinical News

Treakisym bendamustine regulatory update

...or refractory low-grade B cell non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). Last December, SymBio...
...Singapore. SymBio granted Eisai exclusive rights to the product in Japan, South Korea and Singapore. SymBio Pharmaceuticals Ltd....
BioCentury | Jul 11, 2016
Clinical News

Fentanyl iontophoretic transdermal system: Phase III started

...which had licensed the product from Johnson & Johnson. Last October, The Medicines Co. granted SymBio...
...and commercialize SyB P-1501 in Japan (see BioCentury, Dec. 17, 2012 & Oct. 26, 2015). SymBio Pharmaceuticals Ltd....
BioCentury | Dec 21, 2015
Clinical News

Oral rigosertib: Additional Phase I/II data

...reported data from the Phase I portion of the trial (see BioCentury, Nov. 17, 2014). SymBio...
...under a 2011 deal (see BioCentury, July 11, 2011). Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. SymBio Pharmaceuticals Ltd....
BioCentury | Oct 26, 2015
Company News

Medicines Co., SymBio deal

...The Medicines Co. granted SymBio an exclusive license to develop and commercialize Ionsys fentanyl iontophoretic transdermal...
...Ionsys from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. SymBio Pharmaceuticals Ltd....
BioCentury | Jul 13, 2015
Clinical News

IV rigosertib: Additional Phase III data

...Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan Product: IV rigosertib ( Estybon...
...company plans to start a Phase III trial of rigosertib in patients with higher-risk MDS. SymBio...
BioCentury | Jan 19, 2015
Financial News

SymBio financial update

...SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan Business: Cancer, Hematology, Autoimmune Date announced: 2015-01-13 Note: SymBio is...
...level I ADR program on the OTC market. Each ADR will represent one common share. SymBio...
Items per page:
1 - 10 of 133